Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
about
Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.Changes in estrone and estradiol levels during follicle development: a retrospective large-scale study.CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patientsCYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.Analysis of the rs10046 polymorphism of aromatase (CYP19) in premenopausal onset of human breast cancer.Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole.Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Clinical implications of estrone sulfate measurement in laboratory medicine.Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.
P2860
Q35661622-B765D98E-FB4E-43F8-A627-F04640F3F4ECQ35709423-06D2611D-26D6-4BC2-B927-457DD25160C3Q35974459-377E3F9B-E24D-4C5B-880E-E69EB3088526Q36606068-DDEED4BB-2279-4113-B0A2-809852693328Q36915182-AE0079BA-EF41-49AF-9151-4B25D570FF16Q37535511-C276ED32-53FE-4B99-AB97-E081C21EA6FAQ37632155-99A78EFC-3CFD-4C3E-953F-8E08C9F2E76AQ38103593-9BE08594-250F-421D-BF1C-2640DB99F7B3Q38737784-DE6B58B4-390D-4C0B-A551-A603F88284EDQ38739248-B5CC7ACC-0CF8-4940-9915-BE34BC00DD75Q38851505-378F9CB2-F87D-4742-873B-9CD8268E5D15Q39037694-F8CDD042-4F98-4E6A-877B-678652AE1531Q47594270-F7228141-8401-46A5-8D80-6EFAC1BA748AQ51072176-86F0968D-E542-40D4-96C4-7C5601A2EB25
P2860
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Plasma estrone sulfate concent ...... cancer treated with letrozole.
@ast
Plasma estrone sulfate concent ...... cancer treated with letrozole.
@en
type
label
Plasma estrone sulfate concent ...... cancer treated with letrozole.
@ast
Plasma estrone sulfate concent ...... cancer treated with letrozole.
@en
prefLabel
Plasma estrone sulfate concent ...... cancer treated with letrozole.
@ast
Plasma estrone sulfate concent ...... cancer treated with letrozole.
@en
P2093
P2860
P50
P1476
Plasma estrone sulfate concent ...... cancer treated with letrozole
@en
P2093
G Cavazzini
M Clavarezza
M Mansutti
M Porpiglia
P2860
P2888
P304
P356
10.1007/S10549-012-2306-Z
P407
P577
2012-11-06T00:00:00Z